Annexin V levels in survivors of early myocardial;Anexina V en pacientes supervivientes de un infarto de miocardio prematuro

Revista Espanola de Cardiologia

Volumn 55, Issue 12, 2002, Pages 1230-1234

  Roldán, Vanessa ^a   Marín, Francisco ^b   Pineda, Javier ^b   Marco, Pascual ^b   Corral, Javier ^c   Climent, Vicente ^b   García, Amaya ^b   Martínez, Juan G ^b   Sogorb, Francisco ^b  

^a Hospital de San Vicente   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^c UNIVERSITY OF MURCIA   (Spain)

Author keywords

Antibodies; Myocardial infarction; Thrombosis

Indexed keywords

AUTOANTIBODY; BETA2 GLYCOPROTEIN 1 ANTIBODY; BIOLOGICAL MARKER; CHOLESTEROL; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOCORTIN 5; LIPOCORTIN 5 ANTIBODY; PHOSPHOLIPID ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ACUTE HEART INFARCTION; ADULT; AGE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE MARKER; FEMALE; FIBRINOGEN BLOOD LEVEL; GENDER; HUMAN; HYPERCOAGULABILITY; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; RISK FACTOR; STATISTICAL ANALYSIS; SURVIVAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0036973303     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0300-8932(02)76794-8     Document Type: Article

References (24)

1. Zimmerman FH, Cameron A, Fisher LD, NG G. Myocardial infarction in young adults: angiographic characterization, risk factors and prognosis (Coronary Artery Surgery Study Registry). J Am Coll Cardiol 1995;26:654-61.
2. Thompson SG, Kienast J, Pyke SDM, Haverkate F, Van de Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995;332:635-41.
3. Jansson JH, Nilsson TK, Jonson O. Von Willebrand factor, tissue plasminogen activator, and dehydroepiandrosterone sulphate predict cardiovascular death in a 10 year follow up of survivors of acute myocardial infarction. Heart 1998;80:334-7.
4. Fernández P, Marco P, Marín F, Roldán V, Sogorb F. The role of tissue plasminogen activator on the progression of the coronary disease. Eur Heart J 2002;23:88.
5. Rand JH, Wu X, Andree HAM, Ross JBA, Rusinova E, Gascon-Lema MG, et al. Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: a «lupus procoagulant» phenomenon. Blood 1998;5:1652-60.
6. Reutelingsperger CPM. Annexins: key regulators of haemostasis, thrombosis and apoptosis. Thromb Haemost 2001;86:413-9.
7. Van Heerde WL, De Groot PG, Reutelingsperger CPM. The complexity of the phospholipid binding protein annexin V. Thromb Haemost 1995;73:172-9.
8. Rand JH. «Annexinopathies» a new class of diseases. N Engl J Med 1999;340:1035-6.
9. Rand JH, Wu X. Antibody-mediated disruption of the annexin-V antithrombotic shield: a new mechanism for thrombosis in the antiphospholipid syndrome. Thromb Haemost 1999;82:649-55.
10. Hughes GRV. The antiphospholipid syndrome: ten years on. Lancet 1993;342:341-4.
11. Asherson RA, Cervera R. Antiphospholipid antibodies and the Heart. Lessons and pitfalls for the cardiologist. Circulation 1991;84:920-3.
12. González Conejero R, Corral J, Roldán V, Martínez C, Marín F, Rivera J, et al. A common polymorfism in the annexin V Kozak sequence (-1C > T) increases translation efficiency and plasma levels of annexia V, an decreases the risk of myocardial infarction in young patients. Blood 2002;100:2081-6.
13. Kaneko N, Matsuda R, Hosoda S, Kajita T, Ohta Y. Measurement of plasma annexin V by ELISA in the early detection of acute myocardial infarction. Clin Chim Acta 1996;251:65-80.
14. Marguet D, Luciani MF, Moynault A, Williamson P, Chimini G. Engulfment of apoptotic cells involves the redistribution of membrane phosphatidil serine on phagocyte and prey. Nat Cell Biol 1999;1:454-6.
15. Hamon Y, Broccardo C, Chambenoit O, Luciani MF, Toti F, Chaslin S, et al. ABC1 promotes engulfment of apoptotic cells and transbilayer redistribution of phosphatidylserine. Nat Cell Biol 2000;2:399-406.
16. Bach R, Rifkin DB. Expresion of tissue factor procoagulant activity: regulation by cytosolic calcium. Proc Natl Acad Sci Usa 1990;87:6995-9.
17. Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD, Fernández-Ortiz A, et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997;95:594-9.
18. Flynn PD, Byrne CD, Baglin TP, Weisserg PL, Bennet MR. Thrombin generation by apoptotic vascular smooth muscle cells. Blood 1997;89:4378-84.
19. Mallat Z, Hugel B, Ohan J, Lesèche G, Freyssinet JM, Tedgui A. Shed membrane microparticles with procoagulant potential of human atherosclerotic plaques. A role for apoptosis in plaque thrombogenicity. Circulation 1999;99:348-53.
20. Willems GM, Janssen MP, Comfurius P, Galli M, Zwaal RF, Bevers EM. Competition of annexin V and cardiolipin antibodies for binding to phosphatidylserine containing membranes. Biochemistry 2000;39:1982-9.
21. Bevers EM, Janssen MP, Willems GM, Zwaal RFA. No evidence for enhanced thrombin formation through displacement of annexin V by antiphospholipid antibodies. Thromb Haemost 2000; 83:792-4.
22. Hamsten A, Norberg R, Björkholm M, De Faire U, Holm G. Antibodies to cardiolipin in young survivors of myocardial infarction with recurrent cardiovascular events. Lancet 1986;1: 113-6.
23. Sletnes KE, Smith P, Abdel Noor M, Arnesen H, Wisloff F. Antiphospholipids antibodies after myocardial infarction and their relation to mortality, reinfarction and non-haemorrhagic stroke. Lancet 1992;339:451-3.
24. Llamas P, Meseguer E, Fernández de Velasco M, Rábano J, Campos ML, Oña R, et al. Enfermedad vascular cerebral y polimorfismo C/T -1 en la secuencia Kozak del gen de ]a anexina V. Haematologica 2001;86(Suppl 2):172.